Astrana Health (NASDAQ:ASTH) Upgraded by Zacks Research to Hold Rating

Astrana Health (NASDAQ:ASTH) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other research firms have also recently weighed in on ASTH. Needham & Company LLC started coverage on shares of Astrana Health in a research report on Friday, December 12th. They set a “buy” rating and a $28.00 price objective on the stock. TD Cowen lowered their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Barclays dropped their price target on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Astrana Health in a research report on Monday, December 29th. Finally, BTIG Research lowered their target price on Astrana Health from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Astrana Health Trading Down 7.2%

Shares of NASDAQ ASTH opened at $27.12 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.27. Astrana Health has a 12 month low of $20.12 and a 12 month high of $39.97. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 142.74, a P/E/G ratio of 0.73 and a beta of 0.87. The business has a fifty day simple moving average of $24.24 and a 200-day simple moving average of $26.84.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.46). Astrana Health had a return on equity of 1.26% and a net margin of 0.33%.The company had revenue of $956.05 million for the quarter, compared to analyst estimates of $952.83 million. During the same quarter in the previous year, the firm posted $0.33 EPS. Astrana Health’s quarterly revenue was up 99.7% on a year-over-year basis. Sell-side analysts predict that Astrana Health will post 1.15 EPS for the current year.

Institutional Investors Weigh In On Astrana Health

Institutional investors have recently made changes to their positions in the company. NorthCrest Asset Manangement LLC raised its stake in Astrana Health by 0.5% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 450,465 shares of the company’s stock valued at $12,343,000 after purchasing an additional 2,084 shares during the last quarter. GAMMA Investing LLC grew its position in Astrana Health by 144.7% during the fourth quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock worth $37,000 after buying an additional 871 shares in the last quarter. Insight Wealth Strategies LLC bought a new position in Astrana Health during the fourth quarter valued at about $3,514,000. Jacobs Levy Equity Management Inc. raised its holdings in Astrana Health by 19.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 500,527 shares of the company’s stock valued at $14,190,000 after acquiring an additional 80,465 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Astrana Health by 5.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 43,855 shares of the company’s stock worth $1,270,000 after acquiring an additional 2,285 shares during the period. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.